関節リウマチに対するサラゾスルファピリジン低用量投与の検討

• Published in: 臨床リウマチ Vol. 20; no. 3; pp. 188 - 193
• Main Authors: 斉藤, 邦明, 清島, 満, 四戸, 隆基, 竹村, 正男, 佐藤, 正夫
• Format: Journal Article
• Language: Japanese
• Published: 一般社団法人 日本臨床リウマチ学会 2008; The Japanese Society for Clinical Rheumatology and Related Research
• Subjects: disease modifying anti-rheumatic drugs; radiological assessment; rheumatoid arthritis; salazosulfapyridine
• ISSN: 0914-8760; 2189-0595
• DOI: 10.14961/cra.20.188

    A clinical evaluation of low dose salazosulfapyridine (SASP) on patients with rheumatoid Arthritis (RA) was performed. Thirty-one cases of RA who had not taken disease modifying anti-rheumatic drugs (DMARD) prior to this study were treated over twelve months with a SASP dosage of 250 mg or 500mg per day. There were 19 cases with a dosage of 250 mg/day and 12 cases with a dosage of 500 mg/day. CRP levels decreased after treatment with SASP compared with the baseline in both groups (p＜0.001). ESR also decreased after treatment in both groups (p＜0.001). Although MMP-3 levels did not show the significant changes among total cases, there was a significant decrease of MMP-3 levels in 250 mg/day cases (p＜0.03). In addition, there were no severe adverse effects through the treatment with low dose SASP. In terms of these results, SASP treatment would be effective for RA patients who have not received DMARD in the past. Furthermore, we must know there are cases whose joint destruction would progress even though CRP levels are decreased.